Tuesday, November 03, 2015 1:02:06 PM
Sales of the inhalable insulin Afrezza continue to disappoint, and that could spell trouble for the heavily indebted company.
MannKind (NASDAQ:MNKD) is set to report its third-quarter financial results on Nov. 9, but its marketing partner Sanofi (NYSE:SNY) has already issued its third-quarter update, and unfortunately for investors, its results don't bode well for MannKind.
Struggling to get a foothold
When Afrezza received FDA approval last year, expectations that it would become a commercial success were high, because the insulin market is worth billions of dollars annually and Afrezza's inhalable formulation had many people thinking diabetics would flock to it to avoid mealtime injections.
That thinking was bolstered when Sanofi signed on last summer to market Afrezza through its highly successful diabetes sales team, a team responsible for turning Sanofi's long-lasting insulin, Lantus, into a multibillion-dollar-per-year blockbuster.
However, hope that Afrezza would deliver a big win for MannKind investors have been mostly dashed, as sales have failed to materialize in any significant way since Sanofi began pitching it in February. In the first quarter, Afrezza sales were roughly $1.1 million, in the second quarter sales were just about $2.2 million, and last Thursday, Sanofi delivered additional bad news when it reported that Afrezza sales had stalled quarter over quarter at 2 million euros, or about $2.2 million at current exchange rates.
Mounting losses
Anticipating a flood of demand, MannKind invested heavily in infrastructure and personnel, and now those investments are taking a big toll on the company's balance sheet.
Last year, MannKind spent $100 million on R&D and $79.4 million on selling, general, and administrative costs, and despite significant layoffs and cutbacks so far this year, MannKind still reported total operating expenses of $24 million in the second quarter. Additional cost-cutting over the summer should allow for MannKind to report an additional decline in operating expenses for the third quarter, but given Afrezza's third-quarter performance, the company's losses probably continued mounting in Q3.
If so, then that's bad news for investors, because MannKind already owes a lot of money to bond investors, its founder, Al Mann, and Sanofi, which is lending MannKind money to cover its share of losses associated with Afrezza. In Q2, MannKind borrowed $15.4 million from Sanofi under that arrangement, bringing the total amount that it's borrowed from Sanofi to $28.4 million. Even after removing deferred payments from Sanofi that are tied to its collaboration deal that appear as liabilities for accounting purposes, overall, MannKind still has about $300 million in liabilities as of June 30.
Because MannKind owes a lot more to its lenders than the $107 million in cash on the books exiting June, the company boasts a worrisome current ratio of 0.43, and since that current ratio provides a quick look at how able a company would be to pay off short-term creditors, a reading below 1 makes me wonder how long MannKind can continue in its current form.
Looking ahead
Investors will get more color into MannKind's financial condition when it reports its own results next week, and if MannKind can't demonstrate that it's cutting expenses quick enough or can't convince investors that it has a good handle on how to overcome disappointing demand for Afrezza, then investors may see shares fall even further than they already have, especially if people begin thinking that Sanofi will exit its relationship with it. In any event, because MannKind's balance sheet isn't bulletproof and Afrezza has yet to catch on, this stock is too risky for new investors to consider buying.
Recent SNY News
- Form IRANNOTICE - Notice of disclosure filed pursuant to Section 219 of the Iran Threat Reduction and Syria Human Rights Act of 2012 (Exchange Act Section 13(r)). • Edgar (US Regulatory) • 02/23/2024 07:02:56 PM
- Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/23/2024 04:15:26 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 02/15/2024 05:09:49 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/14/2024 08:57:49 PM
- Dupixent® (dupilumab) FDA Approved as First and Only Treatment Indicated for Children Aged 1 Year and Older with Eosinophilic Esophagitis (EoE) • GlobeNewswire Inc. • 01/25/2024 07:29:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 01/23/2024 12:23:49 PM
- Sanofi to Buy Assets From Inhibrx in Deal Valued at Up to $2.2 Billion -- Update • Dow Jones News • 01/23/2024 11:05:00 AM
- Wall Street Highlights: Vroom Shuts Down Online Car Sales, Ericsson Warns of Decline Outside China, and More • IH Market News • 01/23/2024 10:40:18 AM
- Inhibrx Announces Sale of INBRX-101 to Sanofi for an aggregate value of up to $2.2B • PR Newswire (US) • 01/23/2024 06:00:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 01/17/2024 06:49:56 PM
- Sanofi Names Brian Foard Head of Specialty-Care Unit • Dow Jones News • 01/09/2024 07:14:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 12/27/2023 04:18:58 PM
- Sanofi Ends Drug Program After Late-Stage Trial in Lung Cancer Fails • Dow Jones News • 12/21/2023 07:25:00 AM
- Innate Pharma Shares Rise after Sanofi Exercises Licensing Option • Dow Jones News • 12/19/2023 12:28:00 PM
- Hasbro Job Cuts, Oracle’s Stock Decline, Google’s Epic Antitrust Loss, and More • IH Market News • 12/12/2023 10:50:47 AM
- Sanofi Terminates Agreement with Maze Therapeutics Following FTC Opposition • Dow Jones News • 12/11/2023 10:18:00 PM
- Sanofi Sees Improvement in Trial Results of Cancer Drug Sarclisa • Dow Jones News • 12/11/2023 06:50:00 AM
- Sanofi Myeloma Drug Sarclisa Met Primary Goal in Late-Stage Trial • Dow Jones News • 12/07/2023 07:34:00 AM
- Sanofi Sees Annual Sales From New Pharma Assets Above $10.8 Billion by 2030 • Dow Jones News • 12/07/2023 07:20:00 AM
- Trending: Merck's Multiple Sclerosis Drug Misses Expectations in Late-Stage Trials • Dow Jones News • 12/06/2023 01:20:00 PM
- Merck Shares Slump After Multiple Sclerosis Drug Fails in Late-Stage Trials • Dow Jones News • 12/06/2023 10:14:00 AM
- Teva Closes Collaboration Deal With Sanofi on IBD Treatment • Dow Jones News • 11/30/2023 02:23:00 PM
- Teva Completes Closing of Exclusive Collaboration Deal to Deliver Inflammatory Bowel Disease Treatment • Business Wire • 11/30/2023 01:30:00 PM
- Trending: Sanofi's Notus Trial Meets Primary Endpoint • Dow Jones News • 11/27/2023 03:31:00 PM
- Sanofi Says Notus Phase 3 Trial of Dupixent Met Primary Endpoint • Dow Jones News • 11/27/2023 07:40:00 AM
Endexx Corporation (EDXC) Leverages Global Market Trends and Legislative Reforms to Spearhead Growth in the Cannabis and Plant-Based Wellness Sectors • EDXC • Mar 27, 2024 3:01 PM
Applied UV, Inc. Announces Pricing of $2.76 Million Registered Direct and Private Placement Priced at the Market Under Nasdaq Rules • AUVI • Mar 27, 2024 2:51 PM
POET and MultiLane Collaborate to Develop High-Speed Pluggable Transceivers for AI Networks • POET • Mar 27, 2024 10:52 AM
Maybacks Global Entertainment Opens 23 More Stations in Important Major Cities • AHRO • Mar 27, 2024 9:00 AM
NxGen Brands Inc. Forecast to Deliver 140% Growth in Q1 2024 • NXGB • Mar 27, 2024 7:30 AM
Kona Gold Beverages, Inc. Strategic Advancements: Covert LLC Introduces Federally Legal D9 Gummies and Revamps Innovative eCommerce Platform, Propelling Toward $12 Million Annual Revenue Goal • KGKG • Mar 26, 2024 8:30 AM